Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma

Kanuni Sultan Suleyman Training and Research Hospital

Status

Completed

Conditions

Moderate Traumatic Brain Injury

Testican-1

Ubiquitin

Treatments

Diagnostic Test: Testican-1

Study type

Observational

Funder types

Other

Identifiers

NCT06537713

2019/159

Details and patient eligibility

About

We aimed to determine if testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course (presence of intraparenchymal pathology) and mortality in patients with moderate traumatic brain injury.

Full description

The study specifically included patients over 18 years of age with moderate TBI (GCS: 9-13) who provided informed consent. The control group consisted of healthy individuals without any disease who voluntarily participated in the study. Patients with moderate TBI were divided into two groups: those with intracranial pathology (Subdural hemorrhage, epidural hemorrhage, subarachnoid hemorrhage, intraparenchymal hemorrhage, and contusion) and those without. Treatment was initiated according to ATLS in patients with moderate TBI, and blood samples taken at the time of admission to the emergency department were placed in Ethylenediaminetetraacetic acid (EDTA) tubes. The relationship between the patient's clinical scoring (GCS, ISS and AIS), brain CT results, and mortality status with testican-1 and ubiquitin levels was compared.

Enrollment

89 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

being over 18 years old
having a GCS score between 9 and 13

Exclusion criteria

under 18 years of age
had missing data
were pregnant
had neurodegenerative disease
had Central Nervous System (CNS) infection
had cerebral palsy
had penetrating head injury (by a cutting or piercing tool such as a firearm, knife, axe)
patients with severe (GCS: 3-8) or mild (GCS: 14-15) TBI